1. Tertiary lymphoid structures critical for prognosis in endometrial cancer patients
- Author
-
Horeweg, N, Workel, HH, Loiero, D, Church, DN, Vermij, L, Leon-Castillo, A, Krog, RT, de Boer, SM, Nout, RA, Powell, ME, Mileshkin, LR, MacKay, H, Leary, A, Singh, N, Juergenliemk-Schulz, IM, Smit, VTHBM, Creutzberg, CL, Koelzer, VH, Nijman, HW, Bosse, T, de Bruyn, M, Horeweg, N, Workel, HH, Loiero, D, Church, DN, Vermij, L, Leon-Castillo, A, Krog, RT, de Boer, SM, Nout, RA, Powell, ME, Mileshkin, LR, MacKay, H, Leary, A, Singh, N, Juergenliemk-Schulz, IM, Smit, VTHBM, Creutzberg, CL, Koelzer, VH, Nijman, HW, Bosse, T, and de Bruyn, M
- Abstract
B-cells play a key role in cancer suppression, particularly when aggregated in tertiary lymphoid structures (TLS). Here, we investigate the role of B-cells and TLS in endometrial cancer (EC). Single cell RNA-sequencing of B-cells shows presence of naïve B-cells, cycling/germinal center B-cells and antibody-secreting cells. Differential gene expression analysis shows association of TLS with L1CAM overexpression. Immunohistochemistry and co-immunofluorescence show L1CAM expression in mature TLS, independent of L1CAM expression in the tumor. Using L1CAM as a marker, 378 of the 411 molecularly classified ECs from the PORTEC-3 biobank are evaluated, TLS are found in 19%. L1CAM expressing TLS are most common in mismatch-repair deficient (29/127, 23%) and polymerase-epsilon mutant EC (24/47, 51%). Multivariable Cox regression analysis shows strong favorable prognostic impact of TLS, independent of clinicopathological and molecular factors. Our data suggests a pivotal role of TLS in outcome of EC patients, and establishes L1CAM as a simple biomarker.
- Published
- 2022